TP53 and hepatocellular carcinoma: COMMD2 is highly expressed in HCC, and COMMD2 promotes the proliferation, migration and tumor immune infiltration of HCC cells, which is associated with poor prognosis, higher histological grade, more advanced clinical stage, lymph node metastasis and the TP53 mutation status in HCC patients (21).